Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:European journal of pharmacology Ročník 875; s. 173040
Hlavní autoři: Ganbaatar, Byambasuren, Fukuda, Daiju, Shinohara, Masakazu, Yagi, Shusuke, Kusunose, Kenya, Yamada, Hirotsugu, Soeki, Takeshi, Hirata, Ken-ichi, Sata, Masataka
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 15.05.2020
Témata:
Adipose Tissue - drug effects
Adipose Tissue - immunology
Adipose Tissue - metabolism
Animals
Aorta, Thoracic - drug effects
Aorta, Thoracic - immunology
Aorta, Thoracic - pathology
Atherosclerosis
Benzhydryl Compounds - administration & dosage
Blood Glucose - analysis
Blood Glucose - drug effects
Diabetes Mellitus, Experimental - blood
Diabetes Mellitus, Experimental - chemically induced
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - drug therapy
Eicosanoids - metabolism
Empagliflozin
Endothelial function
Endothelium, Vascular - drug effects
Endothelium, Vascular - immunology
Endothelium, Vascular - pathology
Glucosides - administration & dosage
Humans
Inflammation
Male
Mice
Mice, Knockout, ApoE
Plaque, Atherosclerotic - etiology
Plaque, Atherosclerotic - pathology
Plaque, Atherosclerotic - prevention & control
SGLT2 inhibitor
Sodium-Glucose Transporter 2 Inhibitors - administration & dosage
Streptozocin - toxicity
Empagliflozin
Inflammation
Endothelial function
SGLT2 inhibitor
Atherosclerosis
ISSN:0014-2999, 1879-0712, 1879-0712
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE-/-) mice. Male streptozotocin (STZ) - induced diabetic ApoE-/- mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE-/- mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E2 and thromboxane B2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-α in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE-/- mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0014-2999
1879-0712
1879-0712
DOI:10.1016/j.ejphar.2020.173040